|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the studies published to date, while various IL-5 inhibitors have decreased the numbers of esophageal eosinophils, they have not depleted them to the levels consistent with histologic remission of EoE.
|
31175521 |
2019 |
|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition to evidence of mast cell activation, mucosa from patients with EoE have increased levels of interleukin 5; supporting eosinophilia; and upregulation of gene expression of eotaxin-3, a chemokine important in eosinophil migration.
|
31690395 |
2019 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mepolizumab and reslizumab, two anti-IL-5 antibodies, were studied in children and adults with EoE and resulted in reduction of esophageal tissue and blood eosinophils, but no significant reduction in symptoms.
|
29372536 |
2018 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we have reviewed the current evidence regarding efficacy and safety of monoclonal antibodies including mepolizumab (anti-IL-5), reslizumab (anti-IL-5), QAX576 (anti-IL-13), omalizumab (anti-immunoglobulin-E), and infliximab (anti-TNF-α) in treatment of EoE.
|
29234969 |
2018 |
|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eotaxin-3, IL-5 and IL-13 were overexpressed in EoE.
|
28428721 |
2017 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additional control of Th2 inflammation can be achieved in select asthma patients with biologic therapies such as anti-IL-5 and anti-IL-13 antibodies, which have also been trialed in EoE.
|
28831387 |
2017 |
|
Eosinophilic esophagitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic studies have shown that EoE is associated with single nucleotide polymorphism on genes, which are released by the epithelium and important in atopic inflammation such as thymic stromal lymphopoietin located (TSLP) close to the Th2 cytokine cluster [interleukin (IL)-4, IL-5, IL-13] on chromosome 5q22, Calpain 14, EMSY, and Eotaxin3.
|
26258919 |
2015 |
|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Emerging data elucidating the pathogenesis of PPI-REE have shown that Th2-related inflammatory factors such as interleukin (IL)-13, IL-5, eotaxin-3 and major basic protein (MBP) are elevated in PPI-REE, similar to EoE.
|
26039722 |
2015 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings provide evidence that allergen-induced IL-18 has a significant role in promoting IL-5- and iNKT-dependent EoE pathogenesis.
|
25801352 |
2015 |
|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
At baseline, eotaxin-3/IL-13/IL-5 gene expression was indistinguishable between EoE and PPI-REE, excepting increased IL-5 expression in proximal oesophagus (12.54 vs. 57, P = 0.029).
|
25112708 |
2014 |
|
Eosinophilic esophagitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additional analysis revealed increased IL-5 levels in the esophagus of EE patients, allergen-challenged wild-type mice, and CD2-IL-5 transgenic mice but not in IL-5 intestine transgenic mice.
|
18166354 |
2008 |
|
Eosinophilic esophagitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
With regard to treatment, a rapidly disintegrating epinephrine tablet showed promise for sublingual treatment of anaphylaxis, RNA interference techniques showed promise in creating lower-allergenic foods, and anti-IL-5 showed promise for treatment of eosinophilic esophagitis.
|
17412401 |
2007 |